Urea Level and Depression in Patients with Chronic Kidney Disease.
chronic kidney disease
depression
kidney brain axis
urea
Journal
Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
received:
11
06
2024
revised:
10
07
2024
accepted:
17
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
epublish
Résumé
Depression is common in patients with chronic kidney disease (CKD). Experimental studies suggest the role of urea toxicity in depression. We assessed both the incidence of antidepressant prescriptions and depressive symptoms (measured by CESD (Center for Epidemiologic Depression) scale) in 2505 patients with CKD (Stage 3-4) followed up over 5 years in the Chronic Kidney Disease Renal Epidemiology and Information Network (CKD-REIN) cohort. We used a joint model to assess the association between the serum urea level and incident antidepressant prescriptions, and mixed models for the association between the baseline serum urea level and CESD score over the 5-year follow-up. Among the 2505 patients, 2331 were not taking antidepressants at baseline. Of the latter, 87 started taking one during a median follow-up of 4.6 years. After adjustment for confounding factors, the hazard ratio for incident antidepressant prescription associated with the serum urea level (1.28 [95%CI, 0.94,1.73] per 5 mmol/L increment) was not significant. After adjustment, the serum urea level was associated with the mean change in the CESD score (β = 0.26, [95%CI, 0.11,0.41] per 5 mmol/L increment). Depressive symptoms burden was associated with serum urea level unlike depression events. Further studies are needed to draw firm conclusions and better understand the mechanisms of depression in CKD.
Identifiants
pubmed: 39057966
pii: toxins16070326
doi: 10.3390/toxins16070326
pii:
doi:
Substances chimiques
Urea
8W8T17847W
Antidepressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-IA-COH-2012/3731
Organisme : Fresenius Medical Care
ID : X
Organisme : GlaxoSmithKline (France)
ID : X
Organisme : Boehringer Ingelheim (France)
ID : X
Organisme : Vifor France
ID : X
Organisme : Sanofi-Genzyme
ID : X
Organisme : Baxter (France)
ID : X
Organisme : MSD (France)
ID : X
Organisme : Amgen
ID : X
Organisme : Lilly (France)
ID : X
Organisme : Otsuka Pharmaceutical
ID : X
Organisme : AstraZeneca (France)
ID : X